Organon & Co. (OGN)

From the record

Organon & Co.'s filings since 2020 show no warning events in the scan: no bankruptcy or receivership notice, no debt default notice, no exchange listing notice, no restatement warning, no auditor change, no material cyber incident and no late-report notice (its current reports).

From the record

Organon & Co.'s 7 filed years say what it did: revenue went from $7.8 billion in fiscal 2019 to $6.2 billion in fiscal 2025, down 3.7% a year; it rose in 2 of 6 years; the deepest fall was 21% from fiscal 2019 to fiscal 2022; net income was positive in 7 of 7 of those years (its annual reports).

From the record

Over the 3 fiscal years to 2025-12-31, Organon & Co.'s diluted share count grew about 0.7% a year, and dividends and buybacks returned about 28% of its operating cash flow over 3 years (its filed statements). Its officers and directors filed 2 sales and 2 purchases of their own stock on the open market in the year to 2026-11-10, buying about $855 thousand (their Form 4 filings).

From the record

Return on equity: in the fiscal year ended 2025-12-31, Organon & Co. earned about 25 cents of profit for every dollar of shareholders' money, and gross profitability: its products earned about 26 cents per dollar of everything the company owns. Leverage: it owed about 94 cents per dollar of assets, and net share issuance: its share count grew 0.6% over the year (the filed statements).

From the record

Organon & Co.'s standing among 315 graded names in its industry family: revenue of $6.2 billion in fiscal 2025 ranks in the top 5% by size; a net margin of 3% ranks in the top 21%; revenue growth of 0.2% a year over the last 3 filed years ranks in the bottom 39% (its annual reports).

From the record

Organon & Co.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Morrissey, Joseph T. Jr. (Interim CEO, as filed), filing under that title since 2025-11-17, 12 months (bottom 15% of its family); the 20 officers and directors filing in the last fifteen months have been on the record a median of 5.4 years (bottom 45%); 10 officer or director changes were reported on Form 8-K since 2023-11-13, against the 20 people in charge now (bottom 45%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

Organon & Co.'s room to grow, from the newest filed statements (fiscal 2025): cash of $574 million against debt of $8.6 billion leaves -62.6% of its assets as net cash, bottom 1% of its family; cash from operations less capital spending is 8.7% of revenue (top 23%); a gross margin of 53.3% (bottom 28%); research spending of 5.9% of revenue (bottom 6%) (its annual report).

From the record

Organon & Co.'s growth drivers, from the filed years to fiscal 2025: revenue grew 0.2% a year over the last three filed years against -3.7% over all 7, speeding up (top 23% of its family); the newest year grew -2.9% (bottom 34%); research spending grew -8.1% a year (bottom 34%); capital spending grew -6.2% a year (top 44%) (its annual reports). Organon & Co. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.

From the record

Organon & Co.'s newest year against its own record: revenue of $6.2 billion in fiscal 2025 came in 4.7% below the $6.5 billion its prior three years' pace pointed to (bottom 45% of its family); net income of $187 million against a prior three-year average of $935 million (bottom 18%); a net margin of 3% against 14.9% before (bottom 29%) (its annual reports).